Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as T- Dxd
T-DXd · 1 trial · 1 indication
Occurrence of AEs and SAEs graded according to NCI CTCAE v5.0
| Arm | Type | Description |
|---|---|---|
| Arm 1A: T-DXd, Durvalumab and Cisplatin | EXPERIMENTAL | T-DXd, Durvalumab and Cisplatin |
| Arm 1B: T-DXd, Durvalumab and Carboplatin | EXPERIMENTAL | T-DXd, Durvalumab and Carboplatin |
| Arm 1C: T-DXd, Durvalumab and Pemetrexed | EXPERIMENTAL | T-DXd, Durvalumab and Pemetrexed (Arm not initiated) |
| Arm 1D: T-DXd | EXPERIMENTAL | T-DXd |
| Arm 3A: T-DXd and Volrustomig | EXPERIMENTAL | Drug: T-DXd and Volrustomig T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: Volrustomig Volrustomig: administered as an IV infusion Other Name: Volrustomig |
| Arm 3B: T-DXd, Volrustomig and Carboplatin | EXPERIMENTAL | Drug: T-DXd, Volrustomig and Carboplatin T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: Volrustomig Volrustomig: administered as an IV infusion Other Name: Volrustomig Drug: Carboplatin Carboplatin: administered as an IV infusion |
| Arm 4A: T-DXd and Rilvegostomig | EXPERIMENTAL | T-DXd and Rilvegostomig Drug: T-DXd, Rilvegostomig T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: Rilvegostomig Rilvegostomig: administered as an IV infusion Other Name: Rilvegostomig, AZD2936 |
| Arm 4B T-DXd and Rilvegostomig with Carboplatin | EXPERIMENTAL | Drug: T-DXd, Rilvegostomig and Carboplatin T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: Rilvegostomig Rilvegostomig: administered as an IV infusion Other Name: Rilvegostomig, AZD2936 Drug: Carboplatin Carboplatin: administered as an IV infusion |
| Arm 5A: T-DXd and Volrustomig | EXPERIMENTAL | Drug: T-DXd and volrustomig T-DXd: administered as an IV infusion Other Name: DS-8201a, trastuzumab deruxtecan Biological/Vaccine: Volrustomig Volrustomig: administered as an IV infusion (priming dose in first cycle, fixed dose in subsequent cycles) Other Name: volrustomig |
| Arm 5B: T-DXd and Volrustomig | EXPERIMENTAL | Drug: T-DXd and volrustomig T-DXd: administered as an IV infusion Other Name: DS-8201a, trastuzumab deruxtecan Biological/Vaccine: Volrustomig Volrustomig: administered as an IV infusion (fixed dose from first cycle onward) Other Name: volrustomig |
| Name | Type | Description |
|---|---|---|
| T-DXd | DRUG | T-DXd: administered as an IV infusion |
| Durvalumab | BIOLOGICAL | Durvalumab: administered as an IV infusion |
| Cisplatin | DRUG | Cisplatin: administered as an IV infusion |
| Carboplatin | DRUG | Carboplatin: administered as an IV infusion |
| Pemetrexed | DRUG | Pemetrexed: administered as an IV infusion (drug not used) |
| Volrustomig | DRUG | Volrustomig: administered as an IV infusion |
| Rilvegostomig | DRUG | Rilvegostomig: administered as an IV infusion |
Inclusion criteria: * Histologically documented unresectable locally advanced/metastatic non-squamous NSCLC * Part 1: Progression after 1 or 2 lines of systemic therapy for recurrent or metastatic setting. * Part 3, Part 4 and Part 5: Patients must have tumors that do not harbor known genomic alter...
T-DXd is being studied for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). It is an investigational therapy in Phase 1 clinical development, meaning it has not yet been approved for this indication. The drug is being evaluated in a clinical trial to assess its safety and potential efficacy.
T-DXd targets HER2, a protein that can be present on the surface of cancer cells. The drug is designed to bind to HER2-positive tumors, which are a subset of non-small cell lung cancer cases. This targeting mechanism is the basis for its potential activity against HER2-expressing cancers.
T-DXd is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. AstraZeneca is conducting clinical trials to evaluate the safety and efficacy of T-DXd in patients with locally advanced or metastatic non-small cell lung cancer.
T-DXd is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities for the treatment of non-small cell lung cancer. The ongoing Phase 1 trial is designed to evaluate the safety and tolerability of T-DXd in combination with other agents.
T-DXd is being studied in a Phase 1 clinical trial with the identifier NCT04686305. This trial is titled 'Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC.' The trial is currently recruiting participants and has an enrollment target of 304 patients.
Yes, T-DXd and T-Dxd refer to the same investigational drug. The name T-DXd is the primary designation, while T-Dxd is an alternative spelling. Both names are used to describe the same therapy being developed by AstraZeneca for the treatment of locally advanced or metastatic non-small cell lung cancer.